<DOC>
	<DOCNO>NCT02182310</DOCNO>
	<brief_summary>To demonstrate BI 201335 prolong QT interval placebo . To assess tolerability 1200 mg BI 201335 single dose female subject ( double-blind , randomise , placebo-controlled ) inclusion female subject cross-over part trial .</brief_summary>
	<brief_title>Assessment Effect BI 201335 QT Interval Healthy Female Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy caucasian male female , 18 50 year age Body mass index ( BMI ) range 18.5 29.9 kg/m2 ( BMI calculation : weight kilogram divide square height meter ) Signed write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include blood pressure , pulse rate electrocardiogram ( ECG ) ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment study study Participation another trial investigational drug ( ≤ 30 day prior administration trial ) Heavy smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( ≥ 100 mL within four week prior administration trial ) Any deviation laboratory value consider clinical relevance Excessive physical activity within last week trial trial Hypersensitivity BI 201335 , moxifloxacin relate drug class Homozygous genotype status `` Gilbert '' polymorphism ( Uridine diphosphate ( UDP ) glucuronosyl transferase 1A1 ( UGT1A1 ) *28 , *60 ) Heart rate screen &gt; 85 bpm &lt; 40 bpm Any screen ECG value outside reference range clinical relevance include , limited pulse rate ( PR ) interval &gt; 220 m , QRS interval &gt; 115 m , QTcB ( QT interval , correct heart rate accord Bazett 's formula ) &gt; 470 m , QT ( uncorrected ) &gt; 470 m For Female subject Pregnancy Positive pregnancy test No adequate contraception ( adequate contraception e.g . sterilisation , intrauterine pressure , oral contraceptive ) . Females , surgically sterile ask additionally use barrier contraception method ( e.g . condom , diaphragm spermicide ) Inability maintain adequate contraception whole study period time screen one month last intake Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>